LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "folfiri plus" as a keyword



Photo from wikipedia

Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Cancer Research and Clinical Oncology"

DOI: 10.1007/s00432-022-03979-2

Abstract: Fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab is the standard second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) who are refractory or intolerant to fluoropyrimidines and oxaliplatin. However, the benefits of incorporating fluoropyrimidines into… read more here.

Keywords: line chemotherapy; second line; folfiri plus; plus bevacizumab ... See more keywords
Photo from wikipedia

Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.

Sign Up to like & get
recommendations! Published in 2021 at "Clinical colorectal cancer"

DOI: 10.1016/j.clcc.2021.03.001

Abstract: BACKGROUND Combination therapy comprised of fluoropyrimidine plus irinotecan with an angiogenesis inhibitor is widely used as a second-line treatment for metastatic colorectal cancer (mCRC). PATIENTS AND METHODS This retrospective study evaluated the efficacy and safety… read more here.

Keywords: plus bev; colorectal cancer; treatment; folfiri plus ... See more keywords
Photo by djuls from unsplash

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

Sign Up to like & get
recommendations! Published in 2019 at "Annals of Oncology"

DOI: 10.1093/annonc/mdz387

Abstract: Abstract Background FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to… read more here.

Keywords: bevacizumab; first line; cetuximab bevacizumab; versus ... See more keywords
Photo by joshuanewton from unsplash

Effect of patient age on efficacy of FOLFIRI plus cetuximab vs bevacizumab in 1st-line treatment of metastatic colorectal cancer: An analysis of FIRE-3 (AIO KRK 0306).

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2019.37.15_suppl.3541

Abstract: 3541 Background: FIRE-3 compared 1st-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wt mCRC patients. The subgroup of extended RASwt patients consisted of 400 patients. The median age of… read more here.

Keywords: folfiri plus; bevacizumab; fire; patients years ... See more keywords
Photo from wikipedia

Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies

Sign Up to like & get
recommendations! Published in 2022 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2022.939425

Abstract: Background The first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. When progression occurs… read more here.

Keywords: folfiri plus; egfr antibodies; second line; egfr ... See more keywords